The Combination of Homocysteine and C-Reactive Protein Predicts the Outcomes of Chinese Patients with Parkinson's Disease and Vascular Parkinsonism
暂无分享,去创建一个
Ying Jiang | Xiaohong Chen | Ling Long | Yunqi Xu | Yunqi Xu | Cansheng Zhu | Limin Zhang | Junqiang Yan | Xiaohong Chen | Lijuan Yang | Lianfang Bian | Qing Wang | Qing Wang | Cansheng Zhu | L. Long | Ying Jiang | Lijuan Yang | Junqiang Yan | Limin Zhang | L. Bian
[1] A. Goris,et al. Association of the human leucocyte antigen region with susceptibility to Parkinson's disease , 2010, Journal of Neurology, Neurosurgery & Psychiatry.
[2] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[3] W. Poewe,et al. Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients , 2008, Movement disorders : official journal of the Movement Disorder Society.
[4] H. Benamer,et al. Vascular Parkinsonism: A Clinical Review , 2008, European Neurology.
[5] K. Marder,et al. Mild parkinsonian signs and plasma homocysteine concentration in community-dwelling elderly individuals. , 2007, Archives of neurology.
[6] Z. Pei,et al. Nonmotor symptoms are independently associated with impaired health‐related quality of life in Chinese patients with Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[7] Kwang-Soo Lee,et al. Is There an Association between the Level of High-Sensitivity C-Reactive Protein and Idiopathic Parkinson’s Disease? A Comparison of Parkinson’s Disease Patients, Disease Controls and Healthy Individuals , 2009, European Neurology.
[8] M. Critchley,et al. Arteriosclerotic Parkinsonism , 1930, Edinburgh medical journal.
[9] Y. Chan,et al. Oxidative damage in Parkinson disease: Measurement using accurate biomarkers. , 2010, Free radical biology & medicine.
[10] V. Trkulja,et al. Impact of pre-morbid depression on health-related quality of life in non-demented Parkinson's disease patients. , 2010, Parkinsonism & related disorders.
[11] P. Livrea,et al. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients , 2005, Movement disorders : official journal of the Movement Disorder Society.
[12] S. Bojesen,et al. Elevated plasma YKL‐40 levels and ischemic stroke in the general population , 2010, Annals of neurology.
[13] I. Rektor,et al. Serum inflammatory biomarkers in Parkinson's disease. , 2009, Parkinsonism & related disorders.
[14] J. Jankovic,et al. Clinical correlates of vascular parkinsonism. , 1999, Archives of neurology.
[15] P. Lamberti,et al. Elevated homocysteine levels in Parkinson's Disease: is there anything besides L-dopa treatment? , 2010, Current medicinal chemistry.
[16] Paolo Barone,et al. The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study , 2007, Movement disorders : official journal of the Movement Disorder Society.
[17] A. Lees,et al. The l-dopa response in vascular parkinsonism , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[18] T. Müller,et al. Homocysteine levels after acute levodopa intake in patients with Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.
[19] M. A. van 't Hof,et al. MRI in patients with suspected vascular parkinsonism , 1995, Neurology.
[20] S. Fahn. Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .
[21] H. Benamer,et al. Differentiating vascular parkinsonism from idiopathic Parkinson's disease: A systematic review , 2010, Movement disorders : official journal of the Movement Disorder Society.
[22] Honglei Chen,et al. Peripheral Inflammatory Biomarkers and Risk of Parkinson's Disease , 2007 .
[23] A. Lees,et al. [123I] FP‐CIT spect study in vascular parkinsonism and Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.
[24] T. Müller,et al. Cysteine elevation in levodopa‐treated patients with Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.
[25] P. Livrea,et al. Hyperhomocysteinemia in l‐dopa treated Parkinson's disease patients: effect of cobalamin and folate administration , 2005, European journal of neurology.
[26] Y. Ichihara,et al. Higher C-reactive protein concentration and white blood cell count in subjects with more coronary risk factors and/or lower physical fitness among apparently healthy Japanese. , 2002, Circulation journal : official journal of the Japanese Circulation Society.
[27] S. Przedborski. Inflammation and Parkinson's disease pathogenesis , 2010, Movement disorders : official journal of the Movement Disorder Society.
[28] C. Marsden,et al. Recent Developments in Parkinson's Disease , 1986 .
[29] P. O'Suilleabhain,et al. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. , 2004, Archives of neurology.
[30] R. Diaz-Arrastia,et al. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. , 2003, Archives of neurology.
[31] J. Obeso,et al. Homocysteine and cognitive impairment in Parkinson's disease: A biochemical, neuroimaging, and genetic study , 2009, Movement disorders : official journal of the Movement Disorder Society.
[32] M. Hoehn,et al. Parkinsonism , 1967, Neurology.
[33] Kwang-Soo Lee,et al. Association between high-sensitivity C-reactive protein and risk of early idiopathic Parkinson’s disease , 2011, Neurological Sciences.
[34] J. Hughes,et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[35] M. Somerville,et al. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients , 2009, Movement disorders : official journal of the Movement Disorder Society.
[36] Sudha Seshadri,et al. Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease , 2002 .
[37] G. Logroscino,et al. Hyperhomocysteinemia in levodopa‐treated patients with Parkinson's disease dementia , 2009, Movement disorders : official journal of the Movement Disorder Society.
[38] Andrew J Lees,et al. Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis , 2004, Movement disorders : official journal of the Movement Disorder Society.
[39] A Hofman,et al. Homocysteine and cognitive function in the elderly , 2002, Neurology.
[40] A. Bonnet,et al. [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.